Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C491
http://purl.obolibrary.org/obo/NCIT_C491
|
|---|---|
| Preferred Name | Etoposide |
| Definitions |
A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum. Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum. Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04) |
|---|---|
| prefLabel | Etoposide
|
| label | Etoposide
|
| CHEBI_ID | CHEBI:4911
|
| PDQ_Closed_Trial_Search_ID | 39207
|
| code | C491
|
| Has_Target | |
| prefixIRI | NCIT:C491
|
| in_subset |
See more
See less
|
| Display_Name | Etoposide
|
| Preferred_Name | Etoposide
|
| FDA_UNII_Code | 6PLQ3CP4P3
|
| Is_PCDC_AML_Permissible_Value_For_Variable | |
| Contributing_Source |
CTRP
FDA
PCDC
|
| Chemical_Formula | C29H32O13
|
| Maps_To | Etoposide
|
| CAS_Registry | 33419-42-0
|
| NSC Number | 141540
|
| NCI_Drug_Dictionary_ID | 39207
|
| Legacy Concept Name | Etoposide
|
| Is_PCDC_GCT_Permissible_Value_For_Variable | |
| type | |
| ALT_DEFINITION | A drug used to treat testicular and small cell lung cancers. It is also being studied in the treatment of several other types of cancer. Vepesid blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of podophyllotoxin derivative and a type of topoisomerase inhibitor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 39207
|
| Accepted_Therapeutic_Use_For | Hypereosinophilic syndrome; Kaposi's sarcoma; Langerhans cell histiocytosis; Mobilization of peripheral-blood progenitor cells; Multiple myeloma; Neuroblastoma; Non-small lung cancer; Osteogenic sarcoma
Ovarian cancer; Retinoblastoma; Small cell lung cancer; Soft tissue sarcomas; Testicular cancer; Thymoma; Thyroid cancer; Uterine cancer; Wilms' tumor
Acute leukemia; Adrenal cortical cancer; Brain cancer; Chronic Lymphocytic leukemia; Choriocarcinoma; Esophageal cancer; Ewing's sarcoma; Gastric cancer; Germ Cell cancer; Gestational trophoblastic neoplasms; Hepatocellular cancer; Hodgkin's disease
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0015133
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |